Sarcoidosis complicating treatment with natalizumab for Crohn's disease

C A Parisinos; C W Lees; William Wallace; J Satsangi

doi:10.1136/thx.2010.155762

Sarcoidosis complicating treatment with natalizumab for Crohn's disease

C A Parisinos, C W Lees, William Wallace, J Satsangi

Research output: Contribution to journal › Article › peer-review

Abstract

Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.

Original language	English
Pages (from-to)	1109-10
Number of pages	2
Journal	Thorax
Volume	66
Issue number	12
DOIs	https://doi.org/10.1136/thx.2010.155762
Publication status	Published - 2011

Access to Document

10.1136/thx.2010.155762

Cite this

@article{c0c5dd6f5c9a44b39da457ebef4d5c41,

title = "Sarcoidosis complicating treatment with natalizumab for Crohn's disease",

abstract = "Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.",

author = "Parisinos, {C A} and Lees, {C W} and William Wallace and J Satsangi",

year = "2011",

doi = "10.1136/thx.2010.155762",

language = "English",

volume = "66",

pages = "1109--10",

journal = "Thorax",

publisher = "BMJ Publishing Group",

number = "12",

}

TY - JOUR

T1 - Sarcoidosis complicating treatment with natalizumab for Crohn's disease

AU - Parisinos, C A

AU - Lees, C W

AU - Wallace, William

AU - Satsangi, J

PY - 2011

Y1 - 2011

N2 - Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.

AB - Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.

U2 - 10.1136/thx.2010.155762

DO - 10.1136/thx.2010.155762

M3 - Article

C2 - 21233484

VL - 66

SP - 1109

EP - 1110

JO - Thorax

JF - Thorax

IS - 12

ER -

Sarcoidosis complicating treatment with natalizumab for Crohn's disease

Abstract

Access to Document

Fingerprint

Cite this